Lundbeck Romania

Company snapshot

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at the disease areas within psychiatry and neurology.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Lundbeck Romania. Not investment advice.

• trial_data Jun 6, 2026

  Lundbeck Advances Lu AG09222 After Phase 2 Migraine Data

• What is Lundbeck Romania?

  Lundbeck Australia Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Parkinson's Disease. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USP

• Is Lundbeck Romania publicly traded?

  Lundbeck Romania appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Lundbeck Romania develop or market?

  We link 1 drug profile(s) where Lundbeck Romania is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lundbeck-australia-pty-ltd#company-drugs.

• What are the latest developments for Lundbeck Romania?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Lundbeck Romania focus on?

  Lundbeck Romania focuses on Parkinson's Disease based on our analysis of their pipeline programs and drug development activities.